Organon & Co. (OGN) to Release Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGN) will likely be announcing its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $1.59 billion for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Organon & Co. Stock Up 2.8 %

OGN stock opened at $15.04 on Tuesday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The stock’s 50 day simple moving average is $15.35 and its 200 day simple moving average is $17.61. The company has a market cap of $3.87 billion, a P/E ratio of 2.98, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.